#Ancora heart trial#
The CORCINCH-HF pivotal trial is underway, designed to evaluate the safety and efficacy of the AccuCinch® Ventricular Restoration System in patients who have symptomatic heart failure with reduced ejection fraction (HFrEF). By directly treating the left ventricle, the AccuCinch System may help reduce symptoms, improve quality of life and potentially increase life expectancy. The implant is intended to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. For patients in whom HF has progressed beyond the ability of medications and pacemakers to manage symptoms, the AccuCinch System may provide a new treatment option to fill the gap between medication or pacemaker therapy and left ventricular assist devices (LVADs) or a heart transplant.ĭuring the minimally invasive transcatheter AccuCinch System procedure, a flexible implant is attached to the inner wall of the left ventricle and then cinched. The AccuCinch System is an investigational device designed to augment the existing care cardiologists provide their heart failure (HF) patients. Tucker qualified as a chartered accountant in the UK while at Ernst & Young and holds a BS in mathematics from the University of Bristol, England.Ībout the AccuCinch ® Ventricular Restoration System He also held similar positions at Nuvelo and IntraBiotics Pharmaceuticals. Previously, Tucker served as vice president of finance at Sunesis Pharmaceuticals and as principal accounting officer at CymaBay Therapeutics. Tucker is also president and chairman of the Board of the Northern California Chapter of the Association of Bioscience Financial Officers, a position he has held since 2017. Prior to joining Ancora Heart, he served as vice president of finance at Atara Biotherapeutics, Inc., which he joined in 2015. Tucker brings nearly 20 years of experience providing financial leadership for life sciences companies to his role as chief financial officer. I believe that the AccuCinch System has great potential as a treatment option for patients with heart failure and look forward to this opportunity to provide financial leadership to the company." "The core values of the Ancora team, which are focused on helping patients live healthier lives, align strongly with my own. “Bev brings both private and public company board experience as well as significant operating experience, and we are excited to add her talents to our board,” Closs said."Ancora Heart is at a very exciting point in its growth pathway, and I am excited to be joining the team at this stage," said Tucker.
The company also announced that Pagonia Medical co-founder & CEO Beverly Huss joined its board of directors, bringing with her more than 20 years of experience in the medical device space.īefore founding Pagonia, Huss served as president & CEO at Qool Therapeutics, held the roles of co-founder & CEO at Vibrynt and operated in a number of executive positions at Guidant. “We are grateful to our new and returning investors for their support for our vision to provide a promising new treatment option for people suffering from heart failure.” “Ancora Heart is at an exciting stage as we continue with our pivotal clinical trial to support our PMA submission to the FDA, and this investment will help us prepare for potential launch and subsequent commercialization,” Ancora Heart president & CEO Jeff Closs said in the release. Sands Capital, Sio Capital and an undisclosed strategic investor joined all existing investors for the financing round. The company touts it as the only completely transcatheter procedure for treating the enlarged left ventricle. The company won FDA investigational device exemption for AccuCinch in June 2020 and began enrolling patients in the pivotal trial in January of this year.Īncora Heart designed AccuCinch to treat patients with HFrEF by directly reshaping the heart’s left ventricle to address the fundamental issue in the progression of systolic heart failure. Santa Clara, Calif.–based Ancora Heart said in a news release that funds raised in the equity round are earmarked for the acceleration of the Corcinch-HF pivotal clinical study of the AccuCinch system for treating symptomatic heart failure with reduced ejection fraction (HFrEF).
Ancora Heart announced today that it raised $80 million in equity financing for its AccuCinch ventricular restoration system.
0 kommentar(er)
